Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia

Researchers conducted a Phase Ib–II multicenter study of obecabtagene (obe-cel) in adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). Obe-cel resulted in a high incidence of durable response among adults with relapsed or refractory B-cell ALL.